Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Safety and efficacy of concurrent radiation therapy with amivantamab in patients with advanced EGFR- or MET-altered non-small cell lung cancer.

European journal of cancer (Oxford, England : 1990) - 26 Jul 2026

Lavigne Danny, Le Péchoux Cecile, Botticella Angela, Planchard David, Besse Benjamin, Lavaud Pernelle, Gazzah Anas, Jouveshomme Stéphane, Guezour Nadia, Naltet Charles, Pradère Pauline, Remon Jordi, Levy Antonin

Abstract excerpt

INTRODUCTION: Amivantamab is increasingly used in EGFR-altered advanced non-small cell lung cancer (NSCLC), but data on the safety and efficacy of concurrent radiation therapy (RT) remain scarce. This study assessed the safety and efficacy of this approach. METHODS: Patients with advanced EGFR- or MET-altered NSCLC who received RT within 3 weeks after amivantamab were retrospectively analyzed. RT-related adverse...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to Chemoradiotherapy

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Proto-Oncogene Proteins c-met

Share to Treatment Outcome

Source

Identifiers

PMID: 42296899
DOI: 10.1016/j.ejca.2026.116881

Genes

EGFR
MET

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Safety and efficacy of concurrent radiation therapy with amivantamab in patients with advanced EGFR- or MET-altered non-small cell lung cancer.PMID 42296899Read ↗

Real-World Efficacy and Safety of Amivantamab for EGFR-Mutant NSCLC.Semantic proximity Read ↗

Recent Advances in the Management of EGFR Mutated Advanced Non-Small Cell Lung Cancer-A Narrative ReviewSemantic proximity Read ↗

Amivantamab plus chemotherapy versus chemotherapy for first-line treatment of participants with EGFR exon 20 insertion-mutated advanced non-small cell lung cancer: PAPILLON Asia subgroup analysis.Semantic proximity Read ↗

Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions.Semantic proximity Read ↗

Patient-Relevant Outcomes From the Phase III MARIPOSA-2 Trial: Amivantamab-Chemotherapy Versus Chemotherapy in EGFR-Mutant Advanced Non-Small-Cell Lung Cancer Following Disease Progression on Osimertinib.Semantic proximity Read ↗

Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study.Semantic proximity Read ↗

Amivantamab in Participants With Advanced NSCLC and MET Exon 14 Skipping Mutations: Final Results From the CHRYSALIS Study.Semantic proximity Read ↗

Efficacy of Mobocertinib and Amivantamab in Patients With Advanced Non-Small Cell Lung Cancer With EGFR Exon 20 Insertions Previously Treated With Platinum-Based Chemotherapy: An Indirect Treatment Comparison.Semantic proximity Read ↗

Amivantamab Plus Lazertinib in Patients With EGFR-Mutant NSCLC After Progression on Osimertinib and Platinum-Based Chemotherapy: Results From CHRYSALIS-2 Cohort A.Semantic proximity Read ↗

Intracranial and systemic progression on amivantamab in platinum-treated epidermal growth factor receptor exon 20 insertion-mutated advanced non-small cell lung cancerSemantic proximity Read ↗

Amivantamab in advanced non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations: Real-world data from the Italian ATLAS Registry.Semantic proximity Read ↗

Targeting EGFR Exon 20 Insertion Mutation in Non-small cell Lung Cancer: Amivantamab and Mobocertinib.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.